Camber Pharmaceuticals Inc. won final FDA approval Tuesday for its generic 25-mg losartan potassium and hydrochlorothiazide tablets, completing a process that has allowed other generic providers to launch earlier; this new entrant is poised to intensify price competition in this frequently prescribed antihypertensive class.